Thrombocytopenia affects 25–55% of intensive care unit (ICU) patients [1]. The reasons for thrombocytopenia in the ICU are numerous, including, among others, sepsis, drugs, and the use of extracorporeal devices (Fig. 1) [1]. Some patients with thrombocytopenia also have microangiopathic hemolytic anemia (MAHA), accompanied by elevated serum lactate dehydrogenase levels and schistocytes on the blood film [2, 3]. This combination of thrombocytopenia and MAHA, in which thrombi form in the microvasculature and schistocytes develop from red cell destruction as they pass over these thrombi [2], occurs in patients with disseminated intravascular coagulation (DIC), but also in those with thrombotic microangiopathies (TMAs), including thrombotic thrombocytopenic purpura (TTP) and hemolytic uremic syndrome (HUS).